The SOCS Box of SOCS-1 Accelerates Ubiquitin-dependent Proteolysis of TEL-JAK2
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Fusion of the TEL gene on 12p13 to the JAK2 tyrosine kinase gene on 9p24 has been found in human leukemia. TEL-mediated oligomerization of JAK2 results in constitutive activation of the tyrosine kinase (JH1) domain and confers cytokine-independent proliferation on interleukin-3-dependent Ba/F3 cells. Forced expression of the JAK inhibitor gene SOCS1/JAB/SSI-1 induced apoptosis of TEL-JAK2-transformed Ba/F3 cells. This suppression of TEL-JAK2 activity was dependent on SOCS box-mediated proteasomal degradation of TEL-JAK2 rather than on kinase inhibition. Degradation of JAK2 depended on its phosphorylation and its high affinity binding with SOCS1 through the kinase inhibitory region and the SH2 domain. It has been demonstrated that von Hippel-Lindau disease (VHL) tumor-suppressor gene product possesses the SOCS box that forms a complex with Elongin B and C and Cullin-2, and it functions as a ubiquitin ligase. The SOCS box of SOCS1/JAB has also been shown to interact with Elongins; however, ubiquitin ligase activity has not been demonstrated. We found that the SOCS box interacted with Cullin-2 and promoted ubiquitination of TEL-JAK2. Furthermore, overexpression of dominant negative Cullin-2 suppressed SOCS1-dependent TEL-JAK2 degradation. Our study demonstrates the substrate-specific E3 ubiquitin-ligase-like activity of SOCS1 for activated JAK2 and may provide a novel strategy for the suppression of oncogenic tyrosine kinases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ablation of TCEB2, a binding partner of SOCS1, also improved tumor clearance, suggesting that the SOCS1/TCEB2 complex restrains T cell responses and is a potential target for immunotherapy (Ilangumaran et al., 2017; Kamizono et al., 2001; Liau et al., 2018).”
From Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function (2018) · cites this paper as Kamizono et al., 2001
Citations
Cites
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
A family of cytokine-inducible inhibitors of signalling
Starr, R., Willson, T. A., Viney, E. M., Murray, L. J. L., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., et al. (1997) · Nature · doi:10.1038/43206 · Cited by 2,066
A new protein containing an SH2 domain that inhibits JAK kinases
Endo, T. A., Masuhara, M., Yokouchi, M., Suzuki, R., Sakamoto, H., Mitsui, K., Matsumoto, A., Tanimura, S., Ohtsubo, M., Misawa, H., et al. (1997) · Nature · doi:10.1038/43213 · Cited by 1,408
Self-citationStructure and function of a new STAT-induced STAT inhibitor
Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., Yoshizaki, K., et al. (1997) · Nature · doi:10.1038/43219 · Cited by 1,040
The Tyrosine Kinase Negative Regulator c-Cbl as a RING-Type, E2-Dependent Ubiquitin-Protein Ligase
Joazeiro, C. A. P., Wing, S. S., Huang, H.-K., Leverson, J. D., Hunter, T., & Liu, Y.-C. (1999) · Science · doi:10.1126/science.286.5438.309 · Cited by 1,034
Levkowitz, G., Waterman, H., Ettenberg, S. A., Katz, M., Tsygankov, A. Y., Alroy, I., Lavi, S., Iwai, K., Reiss, Y., Ciechanover, A., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80231-2 · Cited by 1,001
A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia
Lacronique, V., Boureux, A., Della Valle, V., Poirel, H., Quang, C. T., Mauchauffé, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J., et al. (1997) · Science · doi:10.1126/science.278.5341.1309 · Cited by 791
Alexander, W. S., Starr, R., Fenner, J. E., Scott, C. L., Handman, E., Sprigg, N. S., Corbin, J. E., Cornish, A. L., Darwiche, R., Owczarek, C. M., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80047-1 · Cited by 762
Yoshimura, A., Ohkubo, T., Kiguchi, T., Jenkins, N. A., Gilbert, D. J., Copeland, N. G., Hara, T., & Miyajima, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07281.x · Cited by 753
Self-citationTwenty proteins containing a C-terminal SOCS box form five structural classes
Hilton, D. J., Richardson, R. T., Alexander, W. S., Viney, E. M., Willson, T. A., Sprigg, N. S., Starr, R., Nicholson, S. E., Metcalf, D., & Nicola, N. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.114 · Cited by 733
Research works printed but not linked: 1
- Shuai, 1996, Oncogene, 13, 247
Cited by
Items 101–200 of 314
CUL-4A Is Critical for Early Embryonic Development
Li, B., Ruiz, J. C., & Chun, K. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.14.4997-5005.2002 · Cited by 96
SOCS Proteins Participate in the Regulation of Innate Immune Response Caused by Viruses
Huang, S., Liu, K., Cheng, A., Wang, M., Cui, M., Huang, J., Zhu, D., Chen, S., Liu, M., Zhao, X., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.558341 · Cited by 94
“Studies have shown that SOCS1 and SOCS3 also directly inhibit JAK activity through their KIR domains, which are considered to be pseudo-substrate functions and are essential for inhibiting cytokine signaling (46).”
BackgroundInfluentialLi, B., Jia, N., Kapur, R., & Chun, K. T. (2006) · Blood · doi:10.1182/blood-2005-08-3349 · Cited by 89
Ryo, A., Tsurutani, N., Ohba, K., Kimura, R., Komano, J. A., Nishi, M., Soeda, H., Hattori, S.-I., Perrem, K., Yamamoto, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704831105 · Cited by 94
Self-citationLiu, J., Vasudevan, S., & Kipreos, E. T. (2004) · Development · doi:10.1242/dev.01245 · Cited by 97
“CUL-2 ubiquitin ligase complex components share meiotic and polarity functions In mammals, elongin C has been shown to interact with CUL2 and CUL5, but not with other cullins (Pause et al., 1999; Kamura et al., 2001).”
BackgroundTRIM8 modulates STAT3 activity through negative regulation of PIAS3
Okumura, F., Matsunaga, Y., Katayama, Y., Nakayama, K. I., & Hatakeyama, S. (2010) · Journal of Cell Science · doi:10.1242/jcs.068981 · Cited by 90
“We used TEL-JAK2, which is a fusion protein consisting of human translocated ets leukemia (TEL) (codons 1-162) and mouse JAK2 JH1 domain (codons 839-1127) to activate STAT3 (Kamizono et al., 2001).”
MethodSelf-citationSuppressor of cytokine signalling gene expression is elevated in breast carcinoma
Raccurt, M., Tam, S. P., Lau, P., Mertani, H. C., Lambert, A., García‐Caballero, T., Li, H., Brown, R. J. P., McGuckin, M. A., Morel, G., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601115 · Cited by 93
“British Journal of Cancer (2003) 89, 524 – 532 & 2003 Cancer Research UK All rights reserved 0007 – 0920/03 $25.00 www.bjcancer.com M o le c u la r a n d C e llu la r P a th o lo g y receptor complex (Ram and Waxman, 2000; Kamizono et al, 2001), particularly in the case of CIS.”
BackgroundInfluentialJuskevicius, D., Jucker, D., Klingbiel, D., Mamot, C., Dirnhofer, S., & Tzankov, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0438-7 · Cited by 81
Oncogenic aberrations of cullin-dependent ubiquitin ligases
Guardavaccaro, D., & Pagano, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207413 · Cited by 89
“Moreover, overexpression of Socs1 can efficiently suppress the transforming potential of TelJak2 (Kamizono et al., 2001).”
BackgroundChinen, T., Kobayashi, T., Ogata, H., Takaesu, G., Takaki, H., Hashimoto, M., Yagita∥, H., Nawata, H., & Yoshimura, A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.051 · Cited by 83
Self-citationThe SPRY domain of SSB-2 adopts a novel fold that presents conserved Par-4–binding residues
Masters, S. L., Yao, S., Willson, T. A., Zhang, J., Palmer, K. R., Smith, B. J., Babon, J. J., Nicola, N. A., Norton, R. S., & Nicholson, S. E. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1034 · Cited by 88
“The SOCS box–E3 ligase complex associated with the SH2 domain–containing SOCS proteins has been shown to ubiquitinate target proteins, thereby mediating their proteasomal degradatio”
BackgroundRussell, R. C., Sufan, R. I., Zhou, B. R., Heir, P., Bunda, S., Sybingco, S. S., Greer, S. N., Roche, O., Heathcote, S. A., Chow, V. W. K., et al. (2011) · Nature Medicine · doi:10.1038/nm.2370 · Cited by 83
“Notably, SOCS1 directly binds and targets phosphorylated JAK2 for ubiquitin-mediated degradation via the E3 ubiquitin ligase ECS complex (comprising elongins B and C, Cul2 or Cul5 and SOCS1”
BackgroundWatanabe, D., Ezoe, S., Fujimoto, M., Kimura, A., Saito, Y., Nagai, H., Tachibana, I., Matsumura, I., Tanaka, T., Kanegane, H., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05107.x · Cited by 90
“The TEL-JAK2 expression vector was a gift from Dr A. Yoshimura (Kamizono et al, 2001).”
MethodRegulation of Janus kinases by SOCS proteins
Kershaw, N. J., Murphy, J. M., Lucet, I. S., Nicola, N. A., & Babon, J. J. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130077 · Cited by 76
The Role of Elongin BC-Containing Ubiquitin Ligases
Okumura, F., Matsuzaki, M., Nakatsukasa, K., & Kamura, T. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00010 · Cited by 91
“Cul5-type ubiquitin ligases Substrates References SOCS1 JAK2 Kamizono et al. (2001) Vav De Sepulveda et al. (2000) IRS1 and IRS2 Rui et al. (2002) ElonginA Rpb1 Yasukawa et al. (2008) SSB1, 2, and 4 iNOS Kuang et al. (2010); Nishiya et al. (2011) WSB1 HIPK2 Choi et al. (2005, 2008) D2 Dentice et…”
BackgroundInfluentialZeng, Y., Liu, X.-F., Yang, W., & Zheng, P. (2019) · Oncogene · doi:10.1038/s41388-019-0906-3 · Cited by 81
Qing, Y., Costa‐Pereira, A. P., Watling, D., & Stark, G. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409863200 · Cited by 93
A three-dimensional model of Suppressor Of Cytokine Signalling 1 (SOCS-1)
Giordanetto, F., & Kroemer, R. T. (2003) · Protein Engineering Design and Selection · doi:10.1093/proeng/gzg015 · Cited by 94
“Kamizono et al. provided experimental data supporting this model (Kamizono et al., 2001).”
ResultProtein Phosphatase 2A Regulates the Stability of Pim Protein Kinases
Losman, J. A., Chen, X. P., Vuong, B. Q., Fay, S., & Rothman, P. B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208246200 · Cited by 73
Skjesol, A., Liebe, T., Iliev, D., Thomassen, E., Tollersrud, L. G., Sobhkhez, M., Joensen, L. L., Secombes, C., & Jørgensen, J. B. (2014) · Developmental and Comparative Immunology · doi:10.1016/j.dci.2014.02.009 · Cited by 76
SOC1 inhibits HPV-E7-mediated transformation by inducing degradation of E7 protein
Kamio, M., Yoshida, T., Ogata, H., Douchi, T., Nagata, Y., Inoue, M., Hasegawa, M., Yonemitsu, Y., & Yoshimura, A. (2004) · Oncogene · doi:10.1038/sj.onc.1207453 · Cited by 85
“Therefore, SOCS1 is now believed to function as an adapter molecule to recruit target proteins such as VAV and TEL-JAK2 for ubiquitination and subsequent degradation (Zhang et al., 1999; De Sepulveda et al., 2000; Kamizono et al., 2001).”
BackgroundMethodSelf-citationThe role of endotoxin, TNF-α, and IL-6 in inducing the state of growth hormone insensitivity
Wang, P., Li, N., Li, J., & Li, W.-Q. (2002) · World Journal of Gastroenterology · doi:10.3748/wjg.v8.i3.531 · Cited by 75
Gargan, S., Ahmed, S., Mahony, R., Bannan, C., Napoletano, S., O’Farrelly, C., Borrow, P., Bergin, C. J., & Stevenson, N. J. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.03.006 · Cited by 74
“This ECS enzymatic complex catalyses the poly-ubiquitination of target proteins, such as JAK2, thus marking them for degradation via the 26S proteasome (Kamizono et al., 2001).”
BackgroundBoyle, K., Egan, P., Rakar, S., Willson, T. A., Wicks, I. P., Metcalf, D., Hilton, D. J., Nicola, N. A., Alexander, W. S., Roberts, A. W., et al. (2007) · Blood · doi:10.1182/blood-2007-03-079178 · Cited by 73
Ubiquitin-Specific Protease 13 Regulates IFN Signaling by Stabilizing STAT1
Yeh, H.-M., Yu, C.-Y., Yang, H.-C., Ko, S.-H., Liao, C., & Lin, Y. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300225 · Cited by 74
“For example, a cullin-based E3 ligase facilitates the ubiquitination and degradation of type I IFN receptor IFNAR1 (11), and suppressor of cytokine signaling 1, a component of an E3 ligase, promotes JAK2 polyubiquitination and degradation (12, 13).”
BackgroundRegulation of cytokine receptor signaling by SOCS1
Ilangumaran, S., & Rottapel, R. K. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00020.x · Cited by 81
“JAK2 and its subsequent proteasomal degradation (52, 53).”
BackgroundSuppressors of cytokine signaling: Relevance to gastrointestinal function and disease
Greenhalgh, C. J., Miller, M. E., Hilton, D. J., & Lund, P. K. (2002) · Gastroenterology · doi:10.1053/gast.2002.37068 · Cited by 77
Heuzé, M. L., Guibal, F. C., Banks, C. A., Conaway, J. W., Conaway, R. C., Cayre, Y. E., Benecke, A., & Lutz, P. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413040200 · Cited by 73
Zadjali, F., Pike, A. C. W., Vesterlund, M., Sun, J., Wu, C., Li, S. S. C., Rönnstrand, L., Knapp, S., Bullock, A. N., & Flores-Morales, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.173526 · Cited by 70
Hanada, T., Yoshida, T., Kinjyo, I., Minoguchi, S., Yasukawa, H., Kato, S., Mimata, H., Nomura, Y., Seki, Y., Kubo, M., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106139200 · Cited by 72
Self-citationFXR ligands protect against hepatocellular inflammation via SOCS3 induction
Xu, Z., Huang, G., Gong, W., Zhou, P., Zhao, Y., Zhang, Y., Zeng, Y., Gao, M., Pan, Z., & He, F. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.04.015 · Cited by 71
RACK1 and CIS Mediate the Degradation of BimEL in Cancer Cells
Zhang, W., Cheng, G. Z., Gong, J., Hermanto, U., Zong, C. S., Chan, J. L. ‐., Cheng, J. Q., & Wang, L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802360200 · Cited by 74
Ilangumaran, S., Ramanathan, S., Rose, J. L., Poussier, P., & Rottapel, R. K. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.5.2435 · Cited by 80
Boyle, K., Zhang, J.-G., Nicholson, S. E., Trounson, E., Babon, J. J., McManus, E. J., Nicola, N. A., & Robb, L. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2008.11.002 · Cited by 65
Cullin Ring Ubiquitin Ligases (CRLs) in Cancer: Responses to Ionizing Radiation (IR) Treatment
Fouad, S., Wells, O. S., Hill, M. A., & D’Angiolella, V. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01144 · Cited by 74
“In complex with Cul2, elongin BC subcomplex, and Rbx1, SOCS1 accelerates the UPSmediated degradation of Jak2 (Kamizono et al., 2001), a STAT3-activating tyrosine kinase which when inhibited using a small-molecule inhibitor sensitizes lung cancer cells Frontiers in Physiology | www.frontiersin.org 7…”
BackgroundInfluentialRegulation of TLR signaling and inflammation by SOCS family proteins
Yoshimura, A., Ohishi, H. M. M., Aki, D., & Hanada, T. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0403194 · Cited by 74
“The importance of the SOCS box was probed for its crucial role in the suppression of the oncogenic activity of translocated ets leukemia‐JAK2 by SOCS1 [ 27 , 28] and from data studying mice that were genetically modified to lack only the SOCS box of SOCS1 [29].”
MethodSelf-citationLi, L., Grønning, L. M., Anderson, P. O., Li, S., Edvardsen, K., Johnston, J., Kioussis, D., Shepherd, P. R., & Wang, P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312672200 · Cited by 66
Huang, X., Moore, D. J., Ketchum, R. J., Nunemaker, C. S., Kovatchev, B. P., McCall, A. L., & Brayman, K. L. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0006 · Cited by 67
“After engagement of their targets, which include cytokine signaling intermediates such as Janus kinase and various STAT proteins, the SOCS molecules, through a sequence known as a SOCS box, recruit the ubiquitin-transferase system (345, 346).”
BackgroundSOCS1, a novel interaction partner of p53 controlling oncogene-induced senescence
Mallette, F. A., Calabrese, V., Ilangumaran, S., & Ferbeyre, G. (2010) · Aging · doi:10.18632/aging.100163 · Cited by 69
“This allows the SOCS protein to operate as an adaptor to trigger ubiquitination and degradation of proteins involved in cellular signaling including JAK [11], TEL-JAK2 [12], IRS-1/2 [13], FAK [14], Vav [15] and Mal [16].”
SOCS proteins in infectious diseases of mammals
Delgado-Ortega, M., Marc, D., Dupont, J., Trapp, S., Berri, M., & Meurens, F. (2012) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2012.11.008 · Cited by 65
“The SOCS box interacts with elongin B, elongin C, cullin 5, and with the RING-finger-domain-only protein to recruit E2 ubiquitintransferase (Kamizono et al., 2001; Kamura et al., 2004).”
Wang, J., Wang, J., Hong, W., Zhang, L., Song, L., Shi, Q. W., Shao, Y., Hao, G., Fang, C., Qiu, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26477-4 · Cited by 61
Giordano, C., Barone, I., Vircillo, V., Panza, S., Malivindi, R., Gelsomino, L., PELLEGRINO, M. A., Rago, V., Mauro, L., Lanzino, M., et al. (2016) · Scientific Reports · doi:10.1038/srep21782 · Cited by 63
The Role of Suppressors of Cytokine Signalling in Human Neoplasms
Sasi, W., Sharma, A. K., & Mokbel, K. (2014) · Molecular Biology International · doi:10.1155/2014/630797 · Cited by 65
“In these tumours, failure of other negative regulatory pathways acting upon the JAK-STATpathway, inappropriate regulation of oncogene expression, or inappropriately enhanced oncogene function such as the TEL-JAK2 fusion protein, may well be present, overwhelming the capacity of SOCS proteins to reduce STAT activation.”
BackgroundOTUB1 inhibits CNS autoimmunity by preventing IFN‐γ‐induced hyperactivation of astrocytes
Wang, X., Mulas, F., Yi, W., Brunn, A., Nishanth, G., Just, S., Waisman, A., Brück, W., Deckert, M., & Schlüter, D. (2019) · The EMBO Journal · doi:10.15252/embj.2018100947 · Cited by 60
“In addition, SOCS1 induces K48 ubiquitination and proteasomal degradation of phosphorylated JAK2 by recruiting the Elongin BC complex (Kamizono et al , 2001).”
McCormick, S. M., Gowda, N. M., Fang, J., & Heller, N. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.746164 · Cited by 58
“The E3 ligase tags substrate proteins with ubiquitin for proteasomal degradation, thereby controlling target protein expression levels and activation (31, 33, 56).”
BackgroundSaudemont, A., Hamrouni, A., Marchetti, P., 刘继中, Jouy, N., Hétuin, D., Colucci, F., & Quesnel, B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1627 · Cited by 55
Prolactin and Growth Hormone Signaling
Chilton, B. S., & Hewetson, A. (2005) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(05)68001-5 · Cited by 63
ATRA‐regulated Asb‐2 gene induced in differentiation of HL‐60 leukemia cells
Kohroki, J., Fujita, S., Itoh, N., Yamada, Y., Imai, H., Yumoto, N., Nakanishi, T., & Tanaka, K. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02829-0 · Cited by 57
Haan, S., Wüller, S., Kaczor, J., Rolvering, C., Nocker, T., Behrmann, I., & Haan, C. (2009) · Oncogene · doi:10.1038/onc.2009.155 · Cited by 57
“The members of this protein family contain a central SH2 domain, as well as a C-terminal domain called SOCS-Box, which is required for proteasomal degradation of SOCS-binding partners (De Sepulveda et al., 2000; Frantsve et al., 2001; Kamizono et al., 2001; Rui et al., 2002; Ungureanu et al., 2002).”
BackgroundUpdating interleukin‐6 classic‐ and trans‐signaling
Scheller, J., Grötzinger, J., & Rose‐John, S. (2006) · Signal Transduction · doi:10.1002/sita.200600086 · Cited by 52
BCL10 Mediates Lipopolysaccharide/Toll-like Receptor-4 Signaling through Interaction with Pellino2
Liu, Y., Dong, W., Chen, L., Xiang, R., Xiao, H., De, G., Wang, Z., & Qi, Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400241200 · Cited by 60
Elongin C (ELOC/TCEB1)-associated von Hippel–Lindau disease
Andreou, A., Yngvadóttir, B., Bassaganyas, L., Clark, G. R., Martín, J., Whitworth, J., Cornish, A. J., Houlston, R. S., Rich, P. M., Egan, C. A., et al. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac066 · Cited by 51
Debrincat, M. A., Zhang, J.-G., Willson, T. A., Silke, J., Connolly, L. M., Simpson, R. J., Alexander, W. S., Nicola, N. A., Kile, B. T., & Hilton, D. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609164200 · Cited by 47
Nie, L., Zhao, Y., Wu, W., Yang, Y.-Z., Wang, H.-C., & Sun, X.-H. (2011) · Cell Research · doi:10.1038/cr.2010.165 · Cited by 51
“Since Jak2 ubiquitination is known to involve Elongin and Cul5 [12, 26], it is conceivable that Asb2 could facilitate the ubiquitination of Jak proteins.”
Wang, R., Yang, X., Chang, M., Xue, Z., Wang, W., Bai, L., Zhao, S., & Liu, E. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.752597 · Cited by 54
Babon, J. J., Yao, S., DeSouza, D. P., Harrison, C. F., Fabri, L. J., Liepinsh, E., Scrofani, S. D., Baca, M., & Norton, R. S. (2005) · The FEBS Journal · doi:10.1111/j.1742-4658.2005.05010.x · Cited by 48
IFN-γ and TGF-β, Crucial Players in Immune Responses: A Tribute to Howard Young
Gauthier, T., & Chen, W. (2022) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2022.0132 · Cited by 51
Suppressor of cytokine signaling 3 (SOCS3) in Th2 cells evokes Th2 cytokines, IgE, and eosinophilia
Kubo, M., & Inoue, H. (2006) · Current Allergy and Asthma Reports · doi:10.1007/s11882-006-0007-6 · Cited by 56
“The functional importance of the SOCS box was shown by SOCS1-mediated suppression of the transforming potential of the fusion protein TEL-JAK2 [23, 24 ].”
BackgroundMostecki, J. W., Showalter, B. M., & Rothman, P. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408938200 · Cited by 54
SOCS-1 Localizes to the Microtubule Organizing Complex-Associated 20S Proteasome
Vuong, B. Q., Arenzana, T. L., Showalter, B. M., Losman, J., Chen, X. P., Mostecki, J., Banks, A. S., Limnander, A., Fernandez, N., & Rothman, P. B. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.20.9092-9101.2004 · Cited by 48
“Cul2, a component of the VCB-Cul2 E3 ligase that has been shown to coimmunoprecipitate with SOCS-1 ( 16 , 17, 46), and a protein related to Cul1 which has been found to copurify with the MTOC (10, 12) also cofractionated with the MTOC and SOCS-1 (Fig. 5).”
BackgroundInfluentialCross-regulation of JAK and Src kinases
Ingley, E., & Klinken, S. P. (2006) · Growth Factors · doi:10.1080/08977190500368031 · Cited by 58
“1999), suggesting that these proteins mediate proteasomal degradation (Kamizono et al. 2001).”
BackgroundSuppressor of cytokine signaling proteins as regulators of innate immune signaling
Strebovsky, J., Walker, P., & Dalpke, A. H. (2011) · Frontiers in bioscience · doi:10.2741/4008 · Cited by 49
“All SOCS proteins additionally bear a carboxyterminal SOCS box domain that acts as an E3 ubiquitin ligase (46-48).”
BackgroundKershaw, N. J., Laktyushin, A., Nicola, N. A., & Babon, J. J. (2014) · Growth Factors · doi:10.3109/08977194.2013.877005 · Cited by 42
“, 2010), of the eight members of the SOCS family, only for SOCS1, which promotes the degradation of the TEL-JAK oncoprotein (Kamizono et al., 2001), vav (De Sepulveda et al.”
BackgroundInfluentialLiu, S., Nheu, T. V., Luwor, R. B., Nicholson, S. E., & Zhu, H. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.607184 · Cited by 46
“SPSB1 Negatively Regulates TGF- Signaling by Destabilizing T RII through Enhanced Ubiquitination—Given that the Socs box in Socs family proteins mediates binding to elongin C and elongin B and induces the formation of an E3 ubiquitin ligase complex (35, 37), resulting in protein degradation of the targets (59), we inv…”
BackgroundA novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination
Kapuria, V., Levitzki, A., Bornmann, W. G., Maxwell, D. S., Priebe, W., Sorenson, R. J., Showalter, H. D., Talpaz, M., & Donato, N. J. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.08.002 · Cited by 47
Hanada, T., Kinjyo, I., Inagaki-Ohara, K., & Yoshimura, A. (2003) · Springer eBooks · doi:10.1007/s10254-003-0015-z · Cited by 49
Self-citationMechanisms of SOCS3 Phosphorylation upon Interleukin-6 Stimulation
Sommer, U., Schmid, C., Sobota, R. M., Lehmann, U., Stevenson, N. J., Johnston, J. A., Schaper, F., Heinrich, P. C., & Haan, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506008200 · Cited by 50
Qing, X., Tan, G., Liu, H.-W., Li, W., Ai, J., Xiong, S., Yang, M.-Q., & Wang, T. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01674-z · Cited by 44
v-Abl Signaling Disrupts SOCS-1 Function in Transformed Pre-B Cells
Limnander, A., Danial, N. N., & Rothman, P. B. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.06.041 · Cited by 45
Negative regulation of cytokine signaling and inflammatory diseases
Inagaki-Ohara, K., Hanada, T., & Yoshimura, A. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00070-5 · Cited by 44
Self-citationSignal Transduction: Multiple Pathways, Multiple Options for Therapy
Heldin, C. (2001) · Stem Cells · doi:10.1634/stemcells.19-4-295 · Cited by 47
Ubiquitination-mediated regulation of interferon responses
Fuchs, S. Y. (2012) · Growth Factors · doi:10.3109/08977194.2012.669382 · Cited by 38
“In support, JAK2 ubiquitination and degradation depend on SOCS1 (Kamura et al. 1998; Kamizono et al. 2001; Ungureanu et al. 2002; Ali et al. 2003).”
BackgroundEnforced SOCS1 and SOCS3 expression attenuates Lck-mediated cellular transformation
Yu, Z. (2010) · International Journal of Oncology · doi:10.3892/ijo_00000603 · Cited by 41
Onnebo, S. M. N., Rasighaemi, P., Kumar, J., Liongue, C., & Ward, A. C. (2012) · Haematologica · doi:10.3324/haematol.2012.064659 · Cited by 39
Ubiquitin-mediated NFκB degradation pathway
Xu, H., You, M., Shi, H., & Hou, Y. (2014) · Cellular and Molecular Immunology · doi:10.1038/cmi.2014.99 · Cited by 41
Okumura, A., Rasmussen, A. L., Halfmann, P., Feldmann, F., Yoshimura, A., Feldmann, H., Kawaoka, Y., Harty, R. N., & Katze, M. G. (2015) · Journal of Virology · doi:10.1128/jvi.01736-15 · Cited by 38
“We therefore sought to determine whether increased expression of SOCS3 protein would enhance budding of EBOV VP40 VLPs. Briefly, human HEK293T cells were mock transfected or transfected with a constant amount of VP40 together with increasing amounts of a SOCS3 expression plasmid (Fig.”
BackgroundInfluentialSelf-citationRBX1/ROC1-SCF E3 ubiquitin ligase is required for mouse embryogenesis and cancer cell survival
Jia, L., & Sun, Y. (2009) · Cell Division · doi:10.1186/1747-1028-4-16 · Cited by 39
“RBX1/Cullin-2/Elongin BC/VHL e.g. HIF-α, TEL-JAK2 [27, 28 ]”
A Requirement for SOCS-1 and SOCS-3 Phosphorylation in Bcr-Abl-Induced Tumorigenesis
Qiu, X., Guo, G., Chen, K., Kashiwada, M., Druker, B. J., Rothman, P. B., & Chen, J. (2012) · Neoplasia · doi:10.1596/neo.12230 · Cited by 39
“Because the interaction between SOCS-1 and the Elongin BC complex is thought to link JAK1 to degradation [38,41], we investigated whether Bcr-Abl–dependent phosphorylation of SOCS-1 had any effect on the interaction between SOCS-1 and Elongin C.”
BackgroundSOCS5 and SOCS6 have similar expression patterns in normal and cancer tissues
Yoon, S., Yi, Y., Kim, S. S., Kim, J.-H., Park, W. S., & Nam, S. W. (2011) · Tumor Biology · doi:10.1007/s13277-011-0264-4 · Cited by 40
Maehr, T., Vecino, J. L. G., Wadsworth, S., Wang, T., & Secombes, C. J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.021 · Cited by 37
Bayle, J., Lopez, S., Iwaï, K., Dubreuil, P. C., & Sepulveda, P. D. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.03.093 · Cited by 39
“Previous data in favour of this model included regulation by SOCS1 of VAV [20], JAK2 [17] TEL-JAK2 [18,19], IRS1, IRS2 [21], p65REL [22] and FAK [36].”
MethodInfluentialMinor, K. H., Bournat, J. C., Toscano, N. C., Giger, R. J., & Davies, S. J. A. (2010) · Brain · doi:10.1093/brain/awq304 · Cited by 37
“or by mediation of proteosomal degradation (Krebs and Hilton, 2000; Kamizono et al., 2001; Kile et al., 2002).”
Increased cytoplasmic levels of CIS, SOCS1, SOCS2, or SOCS3 are required for nuclear translocation
Lee, K., Moon, K.-J., Kim, H. S., Yoo, B. C., Park, S., Lee, H., Kwon, S., Lee, E. S., & Yoon, S. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.05.039 · Cited by 35
“creased after proteasome inhibition [11,12].”
Backgroundvan de Geijn, G. M., Gits, J., & Touw, I. P. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0104041 · Cited by 40
“SOCS proteins, characterized by their Src homology (SH)2 domain and their C-terminal SOCS box [8, 9], act in a classical negative-feedback loop to inhibit signaling from a variety of hematopoietic growth factors and cytokines including Epo, interleukin (IL)-2, IL-3, and granulocyte-colony stimulating factor (G-CSF) [1…”
BackgroundInagaki-Ohara, K., Sasaki, A., Matsuzaki, G., Ikeda, T., Hotokezaka, M., Chijiiwa, K., Kubo, M., Yoshida, H., Nawa, Y., & Yoshimura, A. (2005) · Gut · doi:10.1136/gut.2004.062653 · Cited by 37
Self-citationSH2 Domain-Containing Protein-Tyrosine Phosphatases
Neel, B. G., Chan, G., & Dhanji, S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00098-x · Cited by 37
Cullin RING Ligase 5 (CRL-5): Neddylation Activation and Biological Functions
Zhang, S., & Sun, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1025-0_16 · Cited by 32
Reddy, P. N. G., Sargin, B., Choudhary, C., Stein, S., Grez, M., Müller-Tidow, C., Berdel, W., Serve, H., & Brandts, C. (2010) · Blood · doi:10.1182/blood-2010-08-301416 · Cited by 32
Ungureanu, D., & Silvennoinen, O. (2005) · Science s STKE · doi:10.1126/stke.3042005pe49 · Cited by 34
“Furthermore, the SOCS box is required to rescue the full suppressive effect in SOCS1−/− mice and TEL-JAK2–transformed cells (16, 18, 19).”
BackgroundLiu, Y.-Z., Li, J.-J., Zhang, F., Qin, W., Yao, G.-F., He, X.-H., Xue, P., Ge, C., Wan, D., & Gu, J. (2003) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/s0006-291x(02)02971-6 · Cited by 34
SOCS3: A novel therapeutic target for cardioprotection
Yasukawa, H., Nagata, T., Oba, T., & Imaizumi, T. (2012) · JAK-STAT · doi:10.4161/jkst.22435 · Cited by 35
Self-citationWormald, S., & Hilton, D. J. (2007) · Current Opinion in Hematology · doi:10.1097/00062752-200701000-00004 · Cited by 36
Suppressors of cytokine signaling (SOCS) and type 2 diabetes
Feng, X.-T., Tang, H., Leng, J., & Jiang, Q. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3079-8 · Cited by 32
Oh, J., Kim, S.-H., Ahn, S., & Lee, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103415 · Cited by 32
Interleukins and STAT Signaling
Haque, S. J., & Sharma, P. (2006) · Vitamins and hormones · doi:10.1016/s0083-6729(06)74007-9 · Cited by 34
JAK / STAT defects and immune dysregulation, and guiding therapeutic choices
Chaimowitz, N. S., Smith, M. R., & Satter, L. F. (2024) · Immunological Reviews · doi:10.1111/imr.13312 · Cited by 29
“6 There are seven STAT proteins that have been described (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6), which are activated through 4 Janus kinases (Jak1, Jak2, Jak3, and Tyk2).”
BackgroundInteractions between HIV-1 Vif and human ElonginB-ElonginC are important for CBF-β binding to Vif
Wang, X., Wang, X., Zhang, H., Lv, M., Zuo, T., Wu, H., Wang, J., Liu, D., Wang, C., Zhang, J., et al. (2013) · Retrovirology · doi:10.1186/1742-4690-10-94 · Cited by 27
“Kamizono S, Hanada T, Yasukawa H, Minoguchi S, Kato R, Minoguchi M, Hattori K, Hatakeyama S, Yada M, Morita S, et al: The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2.”
BackgroundInfluentialCui, X.-P., Shan, X., Qian, J., Ji, Q.-Q., Wang, L., Wang, X., Li, M., Ding, H., Liu, Q., Chen, L., et al. (2016) · Experimental and molecular pathology (Print) · doi:10.1016/j.yexmp.2016.05.011 · Cited by 23
RETRACTED ARTICLE: SOCS3 inhibits insulin signaling in porcine primary adipocytes
Yang, S., Xu, C.-Q., Wu, J. W., & Yang, G.-S. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0558-7 · Cited by 30
“box-mediated ubiquitination complex [14, 15].”
RetractedMaruoka, M., Kedashiro, S., Ueda, Y., Mizutani, K., & Takai, Y. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.769091 · Cited by 28
“To examine this hypothesis, we utilized the activated form of TEL-JAK2 in which the tyrosine at 1007 is constitutively phosphorylated (38).”
Method
Metadata
- Authors
- Kamizono, S., Hanada, T., Yasukawa, H., Minoguchi, S., Kato, R., Minoguchi, M., Hattori, K., Hatakeyama, S., Yada, M., Morita, S., Kitamura, T., Kato, H., Nakayama, K.-I., & Yoshimura, A.
- Affiliations
- Kurume University (JP)
- Institute of Medical Science, The University of Tokyo (JP)
- Corresponding author
- Yoshimura, Akihiko
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-04
- Volume
- 276
- Issue
- 16
- Pages
- 12530-12538
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2124489640
- Cited by
- 311
- References
- 38
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 4 · 2023: 9 · 2022: 11 · 2021: 11 · 2020: 10 · 2019: 9 · 2018: 8 · 2017: 7 · 2016: 7 · 2015: 6 · 2014: 11 · 2013: 8 · 2012: 22
- FWCI
- 11.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 7127 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- SOCS1, SOCS box, ubiquitin-mediated proteolysis, E3 ubiquitin ligase, CUL2, JAK2 tyrosine kinase, leukemia, ubiquitination, SH2 domain, apoptosis
- MeSH terms
- Suppressor of Cytokine Signaling 1 Protein, Elongin, ETS Translocation Variant 6 Protein, Animals, Binding Sites, Carrier Proteins, Cell Division, Cell Line, Chromosomes, Human, Pair 12, Chromosomes, Human, Pair 9, Humans, Kinetics, Leukemia, Phosphorylation, Recombinant Fusion Proteins, Recombinant Proteins, Repressor Proteins, Transcription Factors, Transfection, Ubiquitins, Oncogene Proteins, Fusion, Mutagenesis, Cell Cycle Proteins, src Homology Domains, Cullin Proteins, Intracellular Signaling Peptides and Proteins, Suppressor of Cytokine Signaling Proteins, Mice, Janus Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.